A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

PHASE3RecruitingINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

October 29, 2024

Primary Completion Date

December 12, 2031

Study Completion Date

December 12, 2031

Conditions
Crohns DiseaseColitis, UlcerativeArthritis, PsoriaticArthritis, Juvenile
Interventions
DRUG

Guselkumab

Guselkumab will be administered as subcutaneous injection.

Trial Locations (18)

15706

RECRUITING

Hosp. Clinico Univ. de Santiago, Santiago de Compostela

22081

RECRUITING

Schon Klinik Hamburg Eilbek, Hamburg

34764

RECRUITING

Umraniye Training and Research Hospital, Istanbul

84113

RECRUITING

University of Utah, Salt Lake City

100020

RECRUITING

Capital Center For Children's health Capital Medical University, Beijing

110055

RECRUITING

Shengjing Hospital Of China Medical University, Shenyang

200025

RECRUITING

Ruijin Hospital Shanghai Jiao Tong University, Shanghai

213003

RECRUITING

Changzhou No 2 Peoples Hospital, Changzhou

310005

RECRUITING

The Childrens Hospital Zhejiang University School Of Medicine, Hangzhou

310016

RECRUITING

Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou

S2003CVB

RECRUITING

Instituto Caici, Rosario

920 8641

RECRUITING

Kanazawa University Hospital, Kanazawa

650 0017

RECRUITING

Kobe University Hospital, Kobe

861 8520

RECRUITING

Japanese Red Cross Kumamoto Hospital, Kumamoto

849 0937

RECRUITING

Saga University Hospital, Saga

04-501

RECRUITING

Medical Network, Warsaw

04-730

RECRUITING

Instytut Pomnik Centrum Zdrowia Dziecka, Warsaw

06560

RECRUITING

Gazi University Medical Faculty, Ankara

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY